Company news
Catalyst Pharmaceuticals, Inc. news in 2021
Catalyst Pharmaceuticals, Inc.'s news releases, calls and decks from 2021, newest first.
Catalyst Pharmaceuticals Announces DyDo Pharma Initiation of a Phase 3 Study for FIRDAPSE® (amifampridine) in Japan
December 5, 2021
Catalyst Pharmaceuticals to Participate at the Piper Sandler 33rd Annual Virtual Healthcare Conference
November 14, 2021
Catalyst Pharmaceuticals Reports Third Quarter 2021 Financial Results
November 8, 2021
Catalyst Pharmaceuticals to Report Third Quarter 2021 Financial Results on November 9, 2021
October 24, 2021
Catalyst Pharmaceuticals Receives Positive Decision from Appeals Court That Supports Orphan Drug Exclusivity for Firdapse® for LEMS
September 29, 2021
Catalyst Pharmaceuticals to Participate at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
September 16, 2021
Catalyst Pharmaceuticals Appoints Mary Coleman as Vice President, Head of Investor Relations
August 15, 2021
Catalyst Pharmaceuticals Announces Second Quarter 2021 Financial Results and Provides Corporate Update
August 8, 2021
Catalyst Pharmaceuticals to Hold Second Quarter 2021 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, August 10th, 2021
July 25, 2021
Catalyst Pharmaceuticals Announces Issuance of U.S. Patent 11,060,128 a Method of Use Patent with Claims Covering Firdapse®
July 18, 2021
Catalyst Pharmaceuticals Expands Leadership Team with Appointment of Preethi Sundaram, Ph.D. as Chief Product Development Officer
July 5, 2021
Catalyst Pharmaceuticals Appoints Pharmaceutical Executive Molly Harper to its Board of Directors
June 28, 2021
Catalyst Pharmaceuticals Comments on Recent Decision by Health Canada to Re-issue an NOC for Ruzurgi®
June 27, 2021
Catalyst Pharmaceuticals Announces Exclusive License and Supply Agreement with DyDo Pharma for the Development and Commercialization of Firdapse® in Japan
June 27, 2021
Catalyst Pharmaceuticals, Inc.’s and KYE Pharmaceuticals’ Lawsuit in Canadian Federal Court Quashes the Notice of Compliance (NOC) for Ruzurgi®
June 2, 2021
Catalyst Pharmaceuticals Announces First Quarter 2021 Financial Results and Provides Business Update
May 9, 2021
Catalyst Pharmaceuticals to Hold First Quarter 2021 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, May 11th, 2021
May 2, 2021
Catalyst Pharmaceuticals Announces $40 Million Share Repurchase Program
March 21, 2021
Catalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2020 Financial Results and Provides Corporate Update
March 14, 2021
Catalyst Pharmaceuticals to Hold Fourth Quarter and Year-End 2020 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, March 16th, 2021
March 3, 2021
Catalyst Pharmaceuticals Announces Support of Rare Disease Day 2021
February 21, 2021
Catalyst Pharmaceuticals Announces Strategic Plan for Product Portfolio Expansion for Long-Term Success and Provides Corporate Update
January 5, 2021